{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T21:24:45Z","timestamp":1792877085306,"version":"4.5.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T00:00:00Z","timestamp":1621468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p><jats:bold>Purpose:<\/jats:bold> To evaluate the clinical differences between pediatric and adult patients with myelin oligodendrocyte glycoprotein antibody-associated encephalomyelitis (MOG-EM).<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We retrospectively reviewed the clinical features of pediatric and adult patients with MOG-EM in our center between November 2015 and October 2020.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Twenty-eight pediatric patients and 25 adults were admitted to our study. Bilateral optic neuritis (BON) was the most common initial phenotype in the pediatric group but less common in the adult group (28.57 vs. 0%, <jats:italic>p<\/jats:italic> = 0.0119). Almost half of the adult patients presented with neuromyelitis optica spectrum disease (NMOSD), which was less prevalent among the pediatrics (48 vs. 21.43%, <jats:italic>p<\/jats:italic> = 0.0414). Visual impairment was the most common symptom in both groups during the initial attack (pediatric group, 39.29%; adult group, 64%) and throughout the full course (pediatric group, 57.14%; adult group, 72%). More pediatric patients suffered from fever than adult patients at onset (pediatric group, 28.57%; adult group, 4%; <jats:italic>p<\/jats:italic> = 0.0442) and throughout the full course (pediatric group, 39.29%; adult group, 12%; <jats:italic>p<\/jats:italic> = 0.0245). Multiple patchy lesions in subcortical white matter (pediatric group, 40.74%; adult group, 45%), periventricular (pediatric group, 25.93%; adult group, 35%), infratentorial (pediatric group, 18.52%; adult group, 30%) and deep gray matter (pediatric group, 25.93%; adult group, 20%) were frequent in all cases, no significant difference was found between the two groups, while bilateral optic nerve involvement was more frequent in pediatric group (61.54 vs. 14.29%, <jats:italic>p<\/jats:italic> = 0.0042) and unilateral optic nerve involvement was higher in adult group (64.29 vs. 15.38%, <jats:italic>p<\/jats:italic> = 0.0052). At the last follow-up, adult patients had a higher average EDSS score (median 1.0, range 0\u20133) than pediatrics (median 0.0, range 0\u20133), though not significant (<jats:italic>p<\/jats:italic> = 0.0752). Patients aged 0\u20139 years (61.54%) and 10\u201318 years (70%), and patients presenting with encephalitis\/meningoencephalitis (100%) and ADEM (75%) were more likely to recover fully.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> Visual impairment was the dominant symptom in both pediatric and adult patients, while fever was more frequent in pediatric patients. Data suggested that BON and bilateral optic nerve involvement were more common in pediatric cases whereas NMOSD and unilateral optic nerve involvement were more prevalent in adults. The younger patients and patients presenting with encephalitis\/meningoencephalitis and ADEM tended to recover better.<\/jats:p>","DOI":"10.3389\/fneur.2021.679430","type":"journal-article","created":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T06:29:08Z","timestamp":1621492148000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["The Clinical, Radiologic, and Prognostic Differences Between Pediatric and Adult Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Encephalomyelitis"],"prefix":"10.3389","volume":"12","author":[{"given":"Jie","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingjuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingfang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingan","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s001090050092","article-title":"Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis","volume":"75","author":"Bernard","year":"1997","journal-title":"J Mol Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1046\/j.1471-4159.1999.0720001.x","article-title":"The structure and function of myelin oligodendrocyte glycoprotein","volume":"72","author":"Johns","year":"1999","journal-title":"J Neurochem."},{"key":"B3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.clineuro.2006.04.006","article-title":"Clinical relevance of antibodies against myelin oligodendrocyte glycoprotein in different clinical types of multiple sclerosis","volume":"109","author":"Zadro","year":"2007","journal-title":"Clin Neurol Neurosurg"},{"key":"B4","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/1742-2094-8-184","article-title":"Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders","volume":"8","author":"Mader","year":"2011","journal-title":"J Neuroinflammation"},{"key":"B5","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrneurol.2013.118","article-title":"The spectrum of MOG autoantibody-associated demyelinating diseases","volume":"9","author":"Reindl","year":"2013","journal-title":"Nat Rev Neurol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/ana.21916","article-title":"Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease","volume":"66","author":"Brilot","year":"2009","journal-title":"Ann Neurol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1136\/jnnp-2014-308346","article-title":"Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein","volume":"86","author":"Baumann","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B8","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.autrev.2015.12.004","article-title":"Anti-MOG antibody: The history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination","volume":"15","author":"Ramanathan","year":"2016","journal-title":"Autoimmun Rev"},{"key":"B9","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","article-title":"MOG encephalomyelitis: international recommendations on diagnosis and antibody testing","volume":"15","author":"Jarius","year":"2018","journal-title":"J Neuroinflammation"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.msard.2018.07.022","article-title":"Retrospective analysis of children with myelin oligodendrocyte glycoprotein antibody-related disorders","volume":"26","author":"Konuskan","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"B11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jneuroim.2018.05.014","article-title":"Different features between pediatric-onset and adult-onset patients who are seropositive for MOG-IgG: A multicenter study in South China","volume":"321","author":"Chen","year":"2018","journal-title":"J Neuroimmunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e731","DOI":"10.1212\/NXI.0000000000000731","article-title":"Clinical and imaging features of children with autoimmune encephalitis and MOG antibodies","volume":"7","author":"Wegener-Panzer","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1177\/1352458513484547","article-title":"International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions","volume":"19","author":"Krupp","year":"2013","journal-title":"Mult Scler"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11940-019-0541-x","article-title":"Treatment Approaches for MOG-Ab-Associated Demyelination in Children","volume":"21","author":"Hacohen","year":"2019","journal-title":"Curr Treat Options Neurol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"868","DOI":"10.3389\/fneur.2019.00868","article-title":"Myelin oligodendrocyte glycoprotein (MOG) antibody diseases in children in central south china: clinical features, treatments, influencing factors, and outcomes","volume":"10","author":"Mao","year":"2019","journal-title":"Front Neurol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1212\/WNL.0000000000004312","article-title":"Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome","volume":"89","author":"Hennes","year":"2017","journal-title":"Neurology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1212\/WNL.0000000000004117","article-title":"Diagnostic algorithm for relapsing acquired demyelinating syndromes in children","volume":"89","author":"Hacohen","year":"2017","journal-title":"Neurology."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1007\/s00415-020-09716-4","article-title":"The clinical profile of NMOSD in Australia and New Zealand","volume":"267","author":"Bukhari","year":"2020","journal-title":"J Neurol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflammation"},{"key":"B20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"102018","DOI":"10.1016\/j.msard.2020.102018","article-title":"Clinical analysis of anti-NMDAR encephalitis combined with MOG antibody in children","volume":"42","author":"Hou","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1007\/s00415-017-8583-z","article-title":"MOG antibody-related disorders: common features and uncommon presentations","volume":"264","author":"Cobo-Calvo","year":"2017","journal-title":"J Neurol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1177\/1352458515587751","article-title":"Clinical and MRI phenotype of children with MOG antibodies","volume":"22","author":"Fernandez-Carbonell","year":"2016","journal-title":"Mult Scler"},{"key":"B24","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA Neurol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1001\/jamaneurol.2019.2940","article-title":"Serial anti\u2013myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes","volume":"77","author":"Water","year":"2020","journal-title":"JAMA Neurol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1001\/jamaneurol.2018.1814","article-title":"Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders","volume":"75","author":"Lopez-Chiriboga","year":"2018","journal-title":"JAMA Neurol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12974-016-0720-6","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients","volume":"13","author":"Pache","year":"2016","journal-title":"J Neuroinflammation"},{"key":"B29","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.pediatrneurol.2018.03.003","article-title":"Clinical characteristics of pediatric optic neuritis with myelin oligodendrocyte glycoprotein seropositive: a cohort study","volume":"83","author":"Chen","year":"2018","journal-title":"Pediatr Neurol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"key":"B31","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3389\/fneur.2018.00217","article-title":"MOG-IgG-associated optic neuritis, encephalitis, and myelitis: lessons learned from neuromyelitis optica spectrum disorder","volume":"9","author":"Dos Passos","year":"2018","journal-title":"Front Neurol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1136\/jnnp-2014-310206","article-title":"MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study","volume":"87","author":"Akaishi","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.679430\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T06:29:10Z","timestamp":1621492150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.679430\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,20]]},"references-count":32,"alternative-id":["10.3389\/fneur.2021.679430"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.679430","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,20]]},"article-number":"679430"}}